Great roundup as always, Naveen. The pace of neurotech advancements is truly impressive especially the growing intersection between AI and non invasive devices. Subsense's nanoparticle approach sounds like a fascinating frontier though the timeline and regulatory hurdles will be key. Curious to hear your take on how video based phenotyping like Frontera's might reshape early diagnostics in the coming years.
I think there's a lot of upside in Autism for innovative diagnostic tools. Unlike legacy markets in diagnostics, e.g. cognitive health, families and parents drive the show with Autism, and the willingness to spend money on getting the best care for one's family, coming from a tech-native market of millennial parents, means that "new" tools like straightforward video-based AI applications has promise.
Great roundup as always, Naveen. The pace of neurotech advancements is truly impressive especially the growing intersection between AI and non invasive devices. Subsense's nanoparticle approach sounds like a fascinating frontier though the timeline and regulatory hurdles will be key. Curious to hear your take on how video based phenotyping like Frontera's might reshape early diagnostics in the coming years.
I think there's a lot of upside in Autism for innovative diagnostic tools. Unlike legacy markets in diagnostics, e.g. cognitive health, families and parents drive the show with Autism, and the willingness to spend money on getting the best care for one's family, coming from a tech-native market of millennial parents, means that "new" tools like straightforward video-based AI applications has promise.